Phosphate binder use, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 465 512 91.3%
AusNZ D2(2002)
D3(2006) 469 508 91.7%
D3(2007) 442 474 93.0%
D4(2010) 290 333 85.9%
D4(2011) 338 388 86.5%
Belgium D2(2002) 481 536 89.5%
D3(2006) 428 495 85.5%
D3(2007) 345 410 82.5%
D4(2010) 357 463 77.4%
D4(2011) 342 449 74.1%
Canada D2(2002) 556 587 95.1%
D3(2006) 503 540 92.5%
D3(2007) 410 443 90.7%
D4(2010) 300 337 87.6%
D4(2011) 384 464 79.5%
France D2(2002) 408 506 82.8%
D3(2006) 438 545 81.0%
D3(2007) 447 540 84.1%
D4(2010) 265 331 79.9%
D4(2011) 347 435 80.6%
Germany D2(2002) 454 559 81.6%
D3(2006) 480 570 85.4%
D3(2007) 522 619 85.5%
D4(2010) 490 613 80.0%
D4(2011) 509 617 82.2%
Italy D2(2002) 444 564 76.7%
D3(2006) 408 506 78.5%
D3(2007) 438 540 77.4%
D4(2010) 456 555 81.5%
D4(2011) 490 592 81.3%
Japan D2(2002) 1,408 1,763 80.9%
D3(2006) 1,550 1,820 85.3%
D3(2007) 1,511 1,839 82.0%
D4(2010) 1,396 1,678 83.1%
D4(2011) 1,382 1,656 83.2%
Spain D2(2002) 556 609 91.3%
D3(2006) 571 659 85.8%
D3(2007) 456 550 82.7%
D4(2010) 504 618 81.7%
D4(2011) 473 585 81.2%
Sweden D2(2002) 492 534 91.6%
D3(2006) 465 530 86.5%
D3(2007) 449 504 88.9%
D4(2010) 388 449 86.6%
D4(2011) 449 514 88.0%
UK D2(2002) 438 552 77.7%
D3(2006) 340 432 79.6%
D3(2007) 271 337 83.1%
D4(2010) 277 368 76.7%
D4(2011) 322 458 70.5%
US D2(2002) 1,919 2,230 86.1%
D3(2006) 1,555 1,791 88.2%
D3(2007) 1,141 1,308 87.0%
D4(2010) 2,790 3,422 77.4%
D4(2011) 3,121 3,829 76.8%

Percent of patients prescribed any phosphate binder in previous week (D2-D3) or at end of study month (D4) , among all patients

Please see additional methodological information in the Data Sources and Methods section.